Cidara Therapeutics developed Cloudbreak® drug-Fc conjugate therapeutics, including CD388, a long-acting, non-vaccine antiviral candidate for prevention of seasonal and pandemic influenza. Company news centered on CD388 clinical data, FDA designations, Phase 3 ANCHOR development, manufacturing and clinical support from BARDA, and periodic financial results.
Later updates covered the completed Merck tender offer, the transition of Cidara's common stock away from Nasdaq trading, and related public-company status changes.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.54%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.13%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
FAQ
What is the current stock price of Cidara Therapeutics (CDTX)?
Cidara Therapeutics (CDTX) last closed at $221.38.
What is the market cap of Cidara Therapeutics (CDTX)?
The market cap of Cidara Therapeutics (CDTX) is approximately $1.6B.